Safety and efficacy of anti-CD30 CAR-T cell therapy in relapsed/refractory classic Hodgkin lymphoma: a systematic review and meta-analysis

Abstract Background Relapsed/refractory classic Hodgkin lymphoma (R/R cHL) remains challenging to treat, and anti-CD30 chimeric antigen receptor T (CAR-T) cell therapy may be effective. This meta-analysis investigates the efficacy and safety of anti-CD30 CAR-T cell therapy for treating R/R cHL. Meth...

詳細記述

書誌詳細
主要な著者: Fanqiao Meng, Maoyuan Xiang, Yu Liu, Dongfeng Zeng
フォーマット: 論文
言語:English
出版事項: BMC 2025-01-01
シリーズ:BMC Cancer
主題:
オンライン・アクセス:https://doi.org/10.1186/s12885-024-13400-5